Our technology and the scientific premise it is founded on is relevant for several diseases, the company focus is currently on neurodegenerative diseases, where Alzheimer’s is first disease indication in the pipeline.

Pre ADx and Alzheimers’s disease


PreADx is a dynamic test that measures the ongoing clearance of Abeta trough the detection of split products from Abeta. The first product, the X-34 abeta monocyte assay, has been CE marked, and is also ready for use as a Research Use Only Product. 

Alzheimer’s disease (AD) is a leading cause of dementia and poses a dramatic global health burden. More than 50 million people are currently living with dementia globally, with a projected increase to 152 million by 2050. The total worldwide cost of dementia is estimated to be US $1 trillion in 2019, and estimated to double by 20302. Although there are over 130 therapeutic candidates currently in pipeline, therapies under development have so far been failing. This in large part due to lack of understanding of the underlying disease mechanisms and the lack of optimal diagnostics tools that would enable for the necessary early diagnosis required for early intervention options. With the recent FDA approval of Biogen’s new Alzheimer’s treatment, Aduhelm, focus is again moving towards early diagnosis and tools for early detection.


Pipeline Overview

Pre Diagnostics has a full pipeline of tools targeting neurodegenerative diseases, where Parkinson’s Disease is the second diagnostic platform under development. Our technology has the potential to move into precision medicine, and the PrePrMdx platform has recently been launched as a new focus area.